Nav: Home

Results of prospective randomized phase III study of the EBMT (Ricmac trial) dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation for patients with myelodysplastic syndrome

May 04, 2017

RICMAC is an international, multi-centre, investigator-based, open-label, randomized phase III trial that involved 18 transplant units in seven countries between May 2004 and December 2012. A total of 129 patients aged 18-65 years were enrolled. In this trial reduced-intensity conditioning (busulfan-based RIC) is compared to standard myeloablative conditioning regimen (MAC) followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML.

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders that are characterised by abnormal cellular maturation that results in cytopenias and variable risk of progression to acute leukemia. It was to address the needs of patients suffering from MDS that the RICMAC trial was set up.

Conditioning is the very high dose chemotherapy treatment that is given in the days before the stem cell transplant. Reducing the intensity of the conditioning regimen may lead to less toxic effects in patients, but there is concern about a higher risk of relapse.

The results of the trial show that engraftment was comparable between both groups. The cumulative incidence of non-relapse mortality after 1 year was 17% after RIC and 25% after MAC. The incidence of relapse at 2 years was 17% after RIC and 15% after MAC, which resulted in a 2-year relapse-free survival and overall survival of 62% and 76% after RIC, and 58% and 63%, respectively, after MAC.

Trial Principal Chief Investigator Professor Nicolaus Kröger from University Hospital Eppendorf in Hamburg, Germany, said "our study shed new lights on expected benefits of reduced-intensity conditioning regimen that can be offered as a curative treatment approach especially in older patients with MDS".
This trial was supported in part by a grant from Pierre Fabre

Clinical trial information: NCT01203228

See online publication:

European Society for Blood and Marrow Transplantation

Related Stem Cell Transplant Articles:

Success of stem cell therapy for diabetes depends on pre-transplant immune condition
Researchers at the Center for Cell-Based Therapy at University of São Paulo (USP) show that the therapeutic effect is relatively short-lived in patients with more autoreactive lymphocytes before treatment.
Long-term outcomes following stem cell transplant for multiple sclerosis
A new study published online by JAMA Neurology examines the long-term outcomes of patients with aggressive forms of multiple sclerosis (MS) who failed to respond to standard therapies and who underwent autologous hematopoietic stem cell transplantation using their own stem cells.
Feng Zhang receives 2016 New York Stem Cell Foundation -- Robertson Stem Cell Prize
The New York Stem Cell Foundation (NYSCF) announced today that Feng Zhang, Ph.D., is the 2016 recipient of the NYSCF -- Robertson Stem Cell Prize for his pioneering advances to edit human and plant genomes using CRISPR-Cas9.
Scientists take aging cardiac stem cells out of semiretirement to improve stem cell therapy
With age, the chromosomes of our cardiac stem cells compress as they move into a state of safe, semiretirement.
Stem cell scientists discover genetic switch to increase supply of stem cells from cord blood
International stem cell scientists, co-led in Canada by Dr. John Dick and in the Netherlands by Dr.
More Stem Cell Transplant News and Stem Cell Transplant Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...